|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 31/517 | |
| A61P 35/00 |
| (11) | Number of the document | 2303276 |
| (13) | Kind of document | T |
| (96) | European patent application number | 09746098.4 |
| Date of filing the European patent application | 2009-05-11 | |
| (97) | Date of publication of the European application | 2011-04-06 |
| (45) | Date of publication and mention of the grant of the patent | 2013-11-13 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/GB2009/050496 |
| Date | 2009-05-11 |
| (87) | Number | WO 2009/138781 |
| Date | 2009-11-19 |
| (30) | Number | Date | Country code |
| 52706 P | 2008-05-13 | US | |
| 110637 P | 2008-11-03 | US |
| (72) |
BOARDMAN, Kay, Alison, GB
HARD, Susan, Elizabeth, GB
DOBSON, Andrew, Hornby, GB
WHITLOCK, Brian, GB
|
| (73) |
AstraZeneca AB,
151 85 Södertälje,
SE
|
| (54) | FUMARATE SALT OF 4-(3-CHLORO-2-FLUOROANILINO)-7-METHOXY-6-{[1-(N-METHYLCARBAMOYLMETHYL)PIPERIDIN-4-YL]OXY}QUINAZOLINE |
| FUMARATE SALT OF 4-(3-CHLORO-2-FLUOROANILINO)-7-METHOXY-6-{[1-(N-METHYLCARBAMOYLMETHYL)PIPERIDIN-4-YL]OXY}QUINAZOLINE |